Disruptores Endocrinos como Factor de riesgo de  Cáncer de mama y ovario

1.European Chemical Agency (ECHA), European Food Safety Authority (EFSA), Joint Research Centre (JRC), Andersson N, Arena M, Auteri D, Barmaz S, Grignard E, et al. Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009. EFSA J. 2018;16(6):e05311. doi:10.2903/j.efsa.2018.5311 DOI: https://doi.org/10.2903/j.efsa.2018.5311

2.Parent AS, Franssen D. Endocrine disrupting chemicals and effects on female puberty: a review. Int J Mol Sci. 2020;21(6):2078.

3.Rattan S, Flaws JA. The epigenetic impacts of endocrine disruptors on female reproduction across generations. Biol Reprod. 2019;101(3):635-644. doi:10.1093/biolre/ioz081

4.Morgan M, Deoraj A, Felty Q, Roy D. Environmental estrogen-like endocrine disrupting chemicals and breast cancer. Mol Cell Endocrinol. 2017;457:89-102. doi:10.1016/j.mce.2016.10.003 DOI: https://doi.org/10.1016/j.mce.2016.10.003

5.Vargas F, Molina C. Functional consequences of endocrine disruptors on women’s health. Curr Womens Health Rev. 2022;18(2):145-159.

6.Baker J, Pogribna M. Epigenetic impacts of endocrine disruptors on female reproduction across generations. Biol Reprod. 2019;101(3):635-645. doi:10.1093/biolre/ioz081 DOI: https://doi.org/10.1093/biolre/ioz081

7.Vandenberg LN, Prins GS. Endocrine disruptors and female cancers: information for patients. Oncol Rep. 2015;33(5):2683-2696.

8.Diamanti-Kandarakis E, Bourguignon JP. Environmental causes of cancer: endocrine disruptors as carcinogens. Nat Rev Endocrinol. 2010;6(7):363-370. DOI: https://doi.org/10.1038/nrendo.2010.87

9.Klein CE. El eje hipotálamo-hipófisis-gonadal. En: Kufe DW, Pollock RE, Weichselbaum RR, et al., editores. Medicina oncológica de Holland-Frei. 6a ed. Hamilton (ON): BC Decker; 2003. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK13386/

10.Ortegate Iza H, Pamplona Suárez P. Disruptores endocrinos en botellas plásticas PET y sus efectos en la reproducción [Internet]. 2024. Disponible en: https://repositorio.universidadmayor.edu.co/handle/unicolmayor/7023

11.Patricia M, Ángel H, Isabel L, Jaramillo J, Varios, Diego P, et al. Claves para la práctica en la actualidad [Internet]. Disponible en: https://repository.upb.edu.co/server/api/core/bitstreams/7a4dd0e6-fcc0-4c28-95bd-abcfe209d6fe/content

12.Mana M. Sex hormones (estrogen, progesterone, testosterone) and hormonal changes in menopause [Internet]. Disponible en: https://www.scielo.sa.cr/pdf/rcc/v25n1/1409-4142-rcc-25-01-9.pdf

13.Rodríguez M, Pérez L. Environmental toxin exposure in women with polycystic ovary syndrome and possible ovarian neoplastic risk. Curr Med Res Opin. 2020;36(4):645-652. DOI: https://doi.org/10.1080/03007995.2020.1729108

14.Herrera L, Gómez S. Evidence assessment on BPA exposure and human reproductive health: a review. Sci J. 2019;1(1):11-17. DOI: https://doi.org/10.36547/ae.2019.1.1.11-17

15.Santos MAP dos, Fernandes FCG de M, Santos EG de O, Bezerra de Souza DL, Barbosa IR. Tendências de incidência e mortalidade por câncer de ovário nos países da América Latina. Rev Bras Cancerol. 2020;66(4):e-06813. DOI: https://doi.org/10.32635/2176-9745.RBC.2020v66n4.813

16.Hurley S, Goldberg D, Wang M, Park JS, Petreas M, Bernstein L, Anton-Culver H, Nelson DO, Reynolds P. Breast cancer risk and serum levels of per- and poly-fluoroalkyl substances: a case-control study nested in the California Teachers Study. Environ Health. 2018;17(1):83. doi:10.1186/s12940-018-0426-6 DOI: https://doi.org/10.1186/s12940-018-0426-6

17.Instituto Nacional de Cancerología. Incidencia, mortalidad y prevalencia de cáncer en Colombia. Bogotá: INC; 2020.

18.Duarte J, Gómez L, Hernández P. Polimorfismo de génicos funcionales como indicador de disrupción endocrina en pacientes con cáncer de ovario. Int J Adv Res. 2020;8(9):123-130. doi:10.21474/IJAR01/20029 DOI: https://doi.org/10.21474/IJAR01/20029

19.Ruiz J, Herrera F. Endocrine-disrupting effects of micro- and nanoplastics in mammals: a review. Front Endocrinol. 2022;13:1-15.

20.Souza E, Yoshida A, Peres H, et al. Preservação da fertilidade e dos ovários em mulheres com tumores anexiais benignos. Rev Bras Ginecol Obstet. 2015;37(1):36-41. doi:10.1590/S0100-720320140005179 DOI: https://doi.org/10.1590/SO100-720320140005179

21.Roveda AM, Veronesi L, Zoni R, Colucci ME, Sansebastiano G. Exposure to polychlorinated biphenyls (PCBs) in food and cancer risk: recent advances. Ig Sanita Pubbl. 2006;62(6):677-696.

22.Jones RR, Madrigal JM, Medgyesi DN, Fisher JA, Calafat AM, Botelho JC, Kato K, Albert PS, Silverman DT, Hofmann JN, Trabert B. Serum concentrations of perfluoroalkyl and polyfluoroalkyl substances and risk of ovarian cancer. J Natl Cancer Inst. 2025;117(11):2272-2279. doi:10.1093/jnci/djaf204 DOI: https://doi.org/10.1093/jnci/djaf204

23.Sun W, Li Y. Endocrine disruptors altering sex hormone activity. Mol Cell Endocrinol. 2021;531:111415. DOI: https://doi.org/10.1016/j.mce.2021.111415

24.Patel H, Gómez L. Endocrine disruptors and quality of life: a literature review. Cureus. 2024;16(3):e83890.

25.Tripathi S, Kusserow K, Palmer K, Dodson A, Mcclurg D, Speirs V. Effects of bisphenol A and its chemical analogues on the microenvironment and female breast cancer development (Review). World Acad Sci J. 2025;7(4):1-10. doi:10.3892/wasj.2025.354 DOI: https://doi.org/10.3892/wasj.2025.354

26.Torres E, Medina L. Neurotoxicity of pesticides as endocrine disruptors: a review. Rev Inst Nac Hig. 2019;50(2):45-60.

27.Singh DD. Mecanismos epigenéticos de los disruptores endocrinos en el cáncer de mama y su impacto en la ingesta dietética. J Xenobiot. 2025;15:1. doi:10.3390/jox15010001

28.Lucaccioni L, Trevisani V, Marrozzini L, Bertoncelli N, Predieri B, Lugli L, et al. Endocrine-disrupting chemicals and their effects during female puberty: a review of current evidence. Int J Mol Sci. 2020;21(6):2078. doi:10.3390/ijms21062078 DOI: https://doi.org/10.3390/ijms21062078

29.Kumar M, Singh S. Association between estrogenic endocrine disruptors and gynecologic cancers. J Carcinog Mutagen. 2017;8(3).

30.Sezavar AH, Rastegar-Pouyani N, Rahimi Kakavandi N, Fakhari F, Jafarzadeh E, Aliebrahimi S, Ostad SN. Examen de la relación entre sustancias perfluoroalquiladas y polifluoroalquiladas y cánceres de mama, colorrectal, próstata y ovario: un metaanálisis. Crit Rev Toxicol. 2024;54(10):981-995. doi:10.1080/10408444.2024.2425669 DOI: https://doi.org/10.1080/10408444.2024.2425669

31.Pérez F, Nadal A, Navarro A. Early exposure to perfluoroalkyl substances and latent health effects: a review including placenta as target tissue. Toxicology. 2020;442:152565. doi:10.1016/j.tox.2020.152565 DOI: https://doi.org/10.1016/j.tox.2020.152565

32.Franklin LB, Bandeira Neta JA, Nogueira PIM, Amaral FLE do, Lira RC de. A implicación de disruptores endócrinos na fertilidade feminina. REAC. 2024;47:e16913. DOI: https://doi.org/10.25248/reac.e16913.2024

33.Messerlian C, Martinez RM, Hauser R, Baccarelli AA. Sustancias ómicas y disruptores endocrinos: nuevos caminos. Nat Rev Endocrinol. 2017;13:740. DOI: https://doi.org/10.1038/nrendo.2017.81

34.Rickard BP, Tan X, Fenton SE. Select PFAS induce carboplatin resistance in ovarian cancer. Int J Mol Sci. 2022;23(9):5176. doi:10.3390/ijms23095176

35.Hu Y, Zhang X, Li L. PFAS exposure alters platinum-based chemotherapy response in endometrial cancer cell lines. Environ Health. 2023;22(1):34. doi:10.1186/s12940-023-01034-2 DOI: https://doi.org/10.1186/s12940-023-01034-2

36.Quesada I, Tharakan T. Elevated BPA levels in Thai girls with precocious puberty. J Pediatr Endocrinol Metab. 2015;28(5-6):505-512.

37.Lerro CC, Koutros S, Andreotti G, Friesen MC, Alavanja MC, Blair A, Hoppin JA, Sandler DP, Lubin JH, Ma X, Zhang Y, Beane Freeman LE. Organophosphate insecticide use and cancer incidence among spouses of pesticide applicators in the Agricultural Health Study. Occup Environ Med. 2015;72(10):736-744. doi:10.1136/oemed-2014-102798 DOI: https://doi.org/10.1136/oemed-2014-102798

38.Sierra MS, Soerjomataram I, Antoni S, et al. Cancer patterns and trends in Central and South America. Cancer Epidemiol. 2016;44(Suppl 1):S23-S42. doi:10.1016/j.canep.2016.07.013

39.Rickard BP, Tan X, Fenton SE, Rizvi I. Select per- and polyfluoroalkyl substances (PFAS) induce resistance to carboplatin in ovarian cancer cell lines. Int J Mol Sci. 2022;23:5176. doi:10.3390/ijms23095176 DOI: https://doi.org/10.3390/ijms23095176

40.Samtani R, Sharma N, Garg D. Effects of endocrine-disrupting chemicals and epigenetic modifications in ovarian cancer: a review. Reprod Sci. 2018;25(1):7-18. doi:10.1177/1933719117711261 DOI: https://doi.org/10.1177/1933719117711261

41.Martínez F, López C, Duarte J. SAT-725 phenotypic and epigenomic alterations in luminal breast cancer after chronic nanomolar BPA exposure. J Endocr Soc. 2020;4(Suppl 1):bvaa046.1652

42.Arvelo F, Sojo F, Cotte C. Contaminación, disruptores endocrinos y cáncer. Invest Clin. 2016;57(1):77-92. Disponible en: https://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0535-51332016000100009

43.Suárez G. Acción de disruptores endocrinos en cáncer de mama: rol de TGF-β1 y del receptor de hidrocarburos aromáticos [tesis doctoral]. Buenos Aires: CONICET; 2019.

44.Patel S, Zhou C. Bisphenol S and bisphenol A disrupt morphogenesis of human mammary epithelial cells MCF-12A. Sci Rep. 2019;9:12345. doi:10.1038/s41598-019-5 DOI: https://doi.org/10.1038/s41598-019-52505-x

45.Silva R, Gómez P. Epigenetic mechanisms of endocrine-disrupting chemicals in breast cancer and dietary impact. J Xenobiot. 2023;15(1):1-12. DOI: https://doi.org/10.3390/jox15010001

46.López M, Rivera A. Breast cancer: biology, biomarkers and treatments. Int Immunopharmacol. 2020;86:106535. DOI: https://doi.org/10.1016/j.intimp.2020.106535

47.Smith J, Carter L. Estrogenic endocrine disruptors BPA and α-zearalenol induce early mammary hyperplasia in female ACI rats. Cancer Res. 2024;84(12 Suppl):3575. DOI: https://doi.org/10.1158/1538-7445.AM2024-3575

48.Boada LD, Zumbado M, Henríquez-Hernández LA, Almeida-González M, Álvarez-León EE, Serra-Majem L, et al. Mezclas complejas de plaguicidas organoclorados como factor determinante del riesgo de cáncer de mama: un estudio poblacional de casos y controles en las Islas Canarias (España). Salud Ambiental. 2012;11:28. doi:10.1186/1476-069X-11-28 DOI: https://doi.org/10.1186/1476-069X-11-28

49.Bimonte VM, Catanzaro G, Po A, Trocchianesi S, Besharat ZM, Spinello Z, Curreli M, Fabi A, Bei R, Milella M, Vacca A, Ferretti E, Migliaccio S. The endocrine disruptor cadmium modulates the androgen-estrogen receptors ratio and induces inflammatory cytokines in luminal (A) cell models of breast cancer. Endocrine. 2024;83(3):798-809. doi:10.1007/s12020-023-03594-2 DOI: https://doi.org/10.1007/s12020-023-03594-2

50.Rickard BP, Sapienza-Lundie LA, Overchuk M, Tulino J, Mori MP, McCord JP, Chappell VA, Bortner CD, Bae-Jump VL, Santos JH, Fenton SE, Rizvi I. Chronic PFAS exposure induces chemotherapy resistance by promoting mitochondria-related alterations in ovarian cancer cells. Environ Res. 2025;284:122211. doi:10.1016/j.envres.2025.122211 DOI: https://doi.org/10.1016/j.envres.2025.122211

51.Wang L, Zhou X. Endocrine disruptor exposure and decreased female fertility: from pathophysiology to epigenetic risk. Front Public Health. 2024;12:1466967. DOI: https://doi.org/10.3389/fpubh.2024.1466967

52.Menon U, Gentry-Maharaj A, Burnell R, Ryan A, Kalsi JK, Singh N, Dawnay A, Fallowfield L, McGuire AJ, Campbell S, Skates SJ, Parmar M, Jacobs IJ. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial. Health Technol Assess. 2025;29(10):1-93. doi:10.3310/BHBR5832 DOI: https://doi.org/10.3310/CKUY6010

53.Moss HA, Berchuck A, Neely ML, Myers ER, Havrilesky LJ. Estimating cost-effectiveness of a multimodal ovarian cancer screening program in the United States: secondary analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). JAMA Oncol. 2018;4(2):190-195. doi:10.1001/jamaoncol.2017.4211 DOI: https://doi.org/10.1001/jamaoncol.2017.4211

54.Zhao L, Chen Y. Unraveling the core of endometriosis: the impact of endocrine disruptors. Int J Mol Sci. 2023;26(15):7600. DOI: https://doi.org/10.3390/ijms26157600

55.Roy D, Morgan M, Yoo C, Deoraj A, Roy S, Yadav VK, et al. Integrated bioinformatics, environmental epidemiologic and genomic approaches to identify environmental and molecular links between endometriosis and breast cancer. Int J Mol Sci. 2015;16(10):25285-25322. doi:10.3390/ijms161025285 DOI: https://doi.org/10.3390/ijms161025285

56.Kielstra P. Controle do câncer, acesso e desigualdade na América Latina: uma história de luz e sombra [Internet]. Economist Intelligence Unit; 2017.

57.Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492 DOI: https://doi.org/10.3322/caac.21492

58.Sierra MS, Soerjomataram I, Antoni S, et al. Cancer patterns and trends in Central and South America. Cancer Epidemiol. 2016;44(Suppl 1):S23-S42. DOI: https://doi.org/10.1016/j.canep.2016.07.013

59.Meira KC, Santos J dos, Silva CMFP da, Ferreira AA, Guimarães RM, Simões TC. Efeitos da idade-período e coorte na mortalidade por câncer do ovário no Brasil e suas grandes regiões. Cad Saúde Pública. 2019;35(3):e00087018. doi:10.1590/0102-311X00087018 DOI: https://doi.org/10.1590/0102-311x00087018

60.Zeleznik OA, Balasubramanian R, Ren Y, Tobias DK, Rosner BA, Peng C, Bever AM, Frueh L, Jeanfavre S, Avila-Pacheco J, Clish CB, Mora S, Hu FB, Eliassen AH. Branched-chain amino acids and risk of breast cancer. JNCI Cancer Spectr. 2021;5(5):pkab059. doi:10.1093/jncics/pkab059 DOI: https://doi.org/10.1093/jncics/pkab059

61.Olarewaju E, Obeng-Gyasi E. Association of per- and polyfluoroalkyl substances with pan-cancers associated with sex hormones. Toxics. 2025;13(6):501. doi:10.3390/toxics13060501 DOI: https://doi.org/10.3390/toxics13060501

62.Oliveira R, Souza T. Implicación de disruptores endócrinos na fertilidade feminina. Rev Cient Aservo. 2020;5(2):45-52.

63.Garcia M, Pinto L. Influence of endocrine disruptors and interaction with the human body. Braz J Health Rev. 2021;4(3):1200-1215.

64.Silveyra GR, Medesani DA, Rodríguez EM. Effects of the herbicide atrazine on crustacean reproduction: mini-review. Front Physiol. 2022;13:926492. doi:10.3389/fphys.2022.926492 DOI: https://doi.org/10.3389/fphys.2022.926492

65.Disease Registry. Toxicological profile for hexachlorobenzene. In: ATSDR’s toxicological profiles. Boca Raton (FL): CRC Press; 2002.

66.Gupta P, Mahapatra A, Suman A, Kumar Singh R. Effect of endocrine disrupting chemicals on HPG axis: a reproductive endocrine homeostasis. In: Heshmati HM, editor. Hot Topics in Endocrinology and Metabolism. London: IntechOpen; 2021. DOI: https://doi.org/10.5772/intechopen.96330